In my third part of my 3 part Q & A with Charles Eggert, CEO of OPX Biotechnologies, he discusses the current state of affairs in the biofuels industry and policy.
ROBERT GLUCK: How do you view the current state of affairs of the American biofuels industry? Biochemicals industry?
In this first part of my three part interview with OPX Biotechnology’s President and CEO Charles Eggert, he discusses his background, this history and mission of OPX and the company’s efficiency directed genome engineering (EDGE) technology.
ROBERT GLUCK: Please tell our readers a little bit about your background.
A new report identified Glycos Biotechnologies Inc. as offering an evolutionary microbial conversion technology that uniquely produces high-value chemicals and fuels from disadvantaged low cost feedstocks.